Company intelligence / Profile preview

SomnoMed

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

SomnoMed commercializes oral appliance therapy devices for the treatment of obstructive sleep apnea. The company has treated over 810,000 patients worldwide as of FY23 with its SomnoDent product line. Clinical studies have demonstrated efficacy, with the SomnoDent Avant showing reduction in Apnea Hypopnea Index from 16.4 events/hour to 5.8 events/hour after three months of use, with patients wearing the device for approximately 7 hours per night.

Therapeutic areas: PulmonologyNeurology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on SomnoMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SomnoMed.

Explore the full profile